Huaren Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Huaren Pharmaceutical Co., Ltd. was founded in May 1998 and is a modern pharmaceutical and health industry group that integrates research and development, production, and sales, focusing on pharmaceuticals, healthcare, medical devices, and medical services. In August 2010, the company was successfully listed on the Shenzhen Stock Exchange, with the stock abbreviation "Huaren Pharmaceutical" and the stock code "300110". In July 2019, the company underwent an equity change, and the Xi'an Qujiang New Area Management Committee became the actual controller of the company. After more than 20 years of exploration and development, the company's business focuses on the fields of nephrology, respiratory, fine anesthesia, and large capacity preparations. It has successively built five major production bases in Qingdao, Rizhao, Xiaogan, Pubei, and Hefei, with a total production capacity of 950 million bags (bottles). All production lines have passed the new version of GMP certification. The company's main products include small volume injections, peritoneal dialysis fluids, therapeutic infusions, basic infusions, medical devices, tablets, capsules, powders, granules, supporting drug packaging, major health products, and raw materials. Currently, there are 98 varieties and 212 specifications of drugs, achieving the integrated development of "raw materials+preparations+pharmaceutical packaging materials". With innovation as the soul of development, in recent years, the company has actively seized strategic development opportunities, focusing on the treatment direction in the fields of nephrology, respiratory science, and fine anesthesia, as well as the screening of new varieties such as high-capacity preparations. It has been benchmarking first-class enterprises at home and abroad, continuously increasing research and development investment, enriching research and development pipelines, enriching product lines, and enhancing sustainable development capabilities. As of the end of 2021, Huaren Pharmaceutical and its subsidiaries have obtained a total of 457 authorized patents, including 94 invention patent authorizations. Among them, Star Pharmaceutical, a wholly-owned subsidiary, is one of the 47 designated production enterprises for Class II psychotropic drug raw materials in China. With mature supply chain integration capabilities, refined cost control systems, and comprehensive quality management, the company's products are widely accepted and recognized by customers. The products have successfully entered more than 30 provinces and cities across the country, more than 1600 hospitals, and the market share is among the top. In 2021, Star Pharmaceuticals successfully won the bid for the fourth batch of national drug centralized procurement for Doxophylline Injection (10ml: 0.1g). Through more than 20 years of exploration and practice, The company has successively won a series of honors such as "National Key Technological Transformation 'Double High and One Excellent' Project", "National AAA Credit Enterprise", "Outstanding Enterprise in the Shandong Pharmaceutical Industry on the 60th Anniversary of the Founding of the People's Republic of China", "Shandong Quality Management Award", "Shandong Famous Brand Product", "Top 100 Comprehensive Strength of Industrial Enterprises in the Chinese Chemical Pharmaceutical Industry", "National Intellectual Property Advantage Demonstration Enterprise", and "Excellent Respiratory System Product Brand". In 2019, Huaren Pharmaceutical was listed in the "Top 500 Chinese Listed Company Brands" with a brand value of 17.07 billion yuan, ranking 271st. In 2020, the company was awarded the honorary title of "2020 National Market Quality Credit AA Level (User Satisfaction Enterprise)" by the China Quality Association. In 2021, it was ranked 87th among the "2020 Top 100 Chinese Pharmaceutical Industry". On April 26, 2022, the company was awarded the Shandong May Day Labor Award. In the future, the company will actively respond to the national "Healthy China" strategy, supported by product strength construction, and actively promote the layout of the pharmaceutical big health strategy through independent research and development and collaborative innovation. It is committed to growing into a pharmaceutical health industry group that integrates the comprehensive coordinated development of raw materials, preparations, medical devices, pharmaceutical packaging materials, and other sectors. |
| Headquarter | Qingdao |
| Establish Date | 5/20/1998 |
| Listed Code | 300110.SZ |
| Listed Date | 8/25/2010 |
| Chairman | Yang Xiaodong. |
| CEO | Li Jian. |
| Website | www.qdhuaren.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
